CD274 and cancer: Similarly, ICB combined with chemotherapy also improved survival rates across various cancers, reducing progression risks in small and non–small cell lung cancers (NSCLCs), triple-negative breast cancer (especially PD-L1–positive tumors), head and neck squamous cell carcinoma, esophageal cancer, urothelial cancer, and biliary tract cancer (5).